ActiGraph, a leading provider of objective patient monitoring solutions for the global research community, today announced the release of a new mobile app for researchers. The iOS compatible ActiLife Mobile app supports in-field communication with the company’s newest generation of wireless-enabled physical activity and sleep/wake monitoring devices, allowing researchers to initiate data capture and view real-time summary data and operating status reports from active devices in the field using an iPhone or iPad.
ActiLife Mobile includes three distinct areas of functionality that offer researchers more flexibility along with an added measure of security against errors and data loss.
Initialization: ActiLife Mobile allows users to configure and initiate data collection for multiple wireless ActiGraph devices from a mobile device. The ability to perform in-field device initializations streamlines project workflow and helps to prevent deployment delays when unforeseen issues arise.
Real-time Summary Data: ActiLife Mobile allows users to perform burst downloads of active wireless devices, providing real-time daily and cumulative statistics on wear time, energy expenditure, steps taken and activity intensity. Researchers are able to quickly assess protocol adherence and intervene as needed.
Device Management: ActiLife Mobile users have the ability to monitor the operating status of active devices, including battery voltage, data collection status, sample rate and amount of recorded data. This critical feature allows the researcher to preemptively identify and correct any issue that may compromise the integrity of a data set.
“ActiLife Mobile was designed specifically to make the researcher’s job easier and more effective by giving them the flexibility to perform many of their tasks outside the lab and without being tethered to a PC workstation.” said Jeremy Wyatt, ActiGraph’s Vice President of Software Engineering. “Perhaps even more important however is the ability to use a mobile device to monitor subject behavior and compliance during data collection. This adds a dynamic element to the study and enables the research team to implement changes in protocol based on real-time information, ultimately saving time and money.”
The ActiLife Mobile iOS app is now available for download in the Apple App Store.
More information about ActiGraph’s wireless and mobile patient monitoring solutions can be found at http://www.actigraphcorp.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.